XML 51 R31.htm IDEA: XBRL DOCUMENT
v3.22.2.2

OPERATING EXPENSES (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2022
Operating Expenses |
DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY | Operating expenses are stated after charging: DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY
Group |  |  | 2022 $ |  |  |  | 2021 $ |  |  |  | 2020 $ |
|  | Year Ended March 31, |
Group |  |  | 2022 $ |  |  |  | 2021 $ |  |  |  | 2020 $ |
Director fees including bonus (excluding Chairman’s bonus) |  |  | 707,385 |  |  |  | 278,224 |  |  |  | 122,101 |
Chairman’s bonus |  |  | - |  |  |  | 1,160,347 |  |  |  | - |
Auditor’s Remuneration (refer to Note 20) * |  |  | 349,665 |  |  |  | 131,511 |  |  |  | 53,402 |
Legal and Professional fees |  |  | 1,143,300 |  |  |  | 343,422 |  |  |  | 195,433 |
(Gain)/Loss on disposal of leases |  |  | (179 | ) |  |  | - |  |  |  | - |
FX Gains and losses |  |  | (13,577 | ) |  |  | 200,061 |  |  |  | 200,061 |
Depreciation |  |  | 2,423 |  |  |  | 1,512 |  |  |  | 212 |
* | This has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the company’s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements. Refer to note 20 where details of auditor’s remuneration has been disclosed. This has no impact on the primary financial statements.

X
- Definition Disclosure of detailed information about operating expenses explanatory. + References No definition available. + Details
Name: | OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory
Namespace Prefix: | OKYO_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | OKYO_DisclosureOperatingExpensesAbstract
Namespace Prefix: | OKYO_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration